RICHTER, J., A. LUBKING, S. SODERLUND, K. LOTFI, B. MARKEVARN, A. SJALANDER, L. STENKE, S. DENEBERG, E. AHLSTRAND, K. MYHR-ERIKSSON, P. PANAYIOTIDIS, T. GEDDE-DAHL, Daniela ŽÁČKOVÁ, Jiří MAYER, U. OLSSON-STROMBERG, F. X. MAHON, S. SAUSSELE, H. HJORTH-HANSEN a P. KOSKENVESA. Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR-final report from AFTER-SKI. Leukemia. London: Nature Publishing Group, 2021, roč. 35, č. 8, s. 2416-2418. ISSN 0887-6924. Dostupné z: https://dx.doi.org/10.1038/s41375-021-01173-w. |
Další formáty:
BibTeX
LaTeX
RIS
@article{1764396, author = {Richter, J. and Lubking, A. and Soderlund, S. and Lotfi, K. and Markevarn, B. and Sjalander, A. and Stenke, L. and Deneberg, S. and Ahlstrand, E. and MyhrandEriksson, K. and Panayiotidis, P. and GeddeandDahl, T. and Žáčková, Daniela and Mayer, Jiří and OlssonandStromberg, U. and Mahon, F. X. and Saussele, S. and HjorthandHansen, H. and Koskenvesa, P.}, article_location = {London}, article_number = {8}, doi = {http://dx.doi.org/10.1038/s41375-021-01173-w}, keywords = {TKI discontinuation; CML; MMR-final report; AFTER-SKI}, language = {eng}, issn = {0887-6924}, journal = {Leukemia}, title = {Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR-final report from AFTER-SKI}, url = {https://www.nature.com/articles/s41375-021-01173-w.pdf}, volume = {35}, year = {2021} }
TY - JOUR ID - 1764396 AU - Richter, J. - Lubking, A. - Soderlund, S. - Lotfi, K. - Markevarn, B. - Sjalander, A. - Stenke, L. - Deneberg, S. - Ahlstrand, E. - Myhr-Eriksson, K. - Panayiotidis, P. - Gedde-Dahl, T. - Žáčková, Daniela - Mayer, Jiří - Olsson-Stromberg, U. - Mahon, F. X. - Saussele, S. - Hjorth-Hansen, H. - Koskenvesa, P. PY - 2021 TI - Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR-final report from AFTER-SKI JF - Leukemia VL - 35 IS - 8 SP - 2416-2418 EP - 2416-2418 PB - Nature Publishing Group SN - 08876924 KW - TKI discontinuation KW - CML KW - MMR-final report KW - AFTER-SKI UR - https://www.nature.com/articles/s41375-021-01173-w.pdf N2 - Discontinuation of tyrosine kinase inhibitor (TKI) treatment for chronic phase (CP) CML patients with a deep molecular response (DMR) has entered standard practice. This is based on numerous clinical studies showing that ~50% of patients with DMR can stop TKI treatment without imminent disease relapse. However, in most of these trials long-term follow-up has been limited. ER -
RICHTER, J., A. LUBKING, S. SODERLUND, K. LOTFI, B. MARKEVARN, A. SJALANDER, L. STENKE, S. DENEBERG, E. AHLSTRAND, K. MYHR-ERIKSSON, P. PANAYIOTIDIS, T. GEDDE-DAHL, Daniela ŽÁČKOVÁ, Jiří MAYER, U. OLSSON-STROMBERG, F. X. MAHON, S. SAUSSELE, H. HJORTH-HANSEN a P. KOSKENVESA. Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR-final report from AFTER-SKI. \textit{Leukemia}. London: Nature Publishing Group, 2021, roč.~35, č.~8, s.~2416-2418. ISSN~0887-6924. Dostupné z: https://dx.doi.org/10.1038/s41375-021-01173-w.
|